What does getting HRT online actually require clinically?
Hormone replacement therapy for menopause and perimenopause involves hormones that have real physiological effects and real contraindications. The clinical standard before prescribing is not negotiable: a licensed clinician must evaluate your symptom history, lab work, and health history before a prescription is written.
This is true whether the provider is in-person or telehealth. A telehealth provider that skips lab review or does not evaluate relevant health history is not operating to the clinical standard — it is operating below it. Before starting any HRT evaluation, confirm that the provider requires labs and that a licensed physician or nurse practitioner reviews them personally before generating a prescription.
What the baseline lab panel includes
The specific panel varies by provider and by what is being prescribed, but a responsible baseline for estrogen and progesterone therapy typically includes:
- Estradiol (E2): To characterize baseline estrogen levels, particularly relevant in the perimenopause transition where levels fluctuate significantly.
- FSH (follicle-stimulating hormone): FSH rises as ovarian reserve declines. An elevated FSH is one marker of menopause transition; FSH above 30 mIU/mL on two tests twelve months apart is one criterion for menopause diagnosis. Context matters — FSH is not diagnostic in isolation.
- LH (luteinizing hormone): Evaluated alongside FSH to characterize the hormonal picture.
- Comprehensive metabolic panel: Liver function, kidney function, and metabolic status — relevant safety baseline before hormonal therapy.
- Lipid panel: Cardiovascular baseline, relevant given the relationship between estrogen therapy and lipid profiles.
- TSH (thyroid-stimulating hormone): Thyroid dysfunction shares symptoms with menopause (fatigue, mood changes, sleep disruption) and should be evaluated before attributing symptoms to menopause alone.
If testosterone for women is being considered (for libido or energy concerns where low testosterone is documented), free and total testosterone and SHBG are also included. Labs from within approximately 60 days are typically accepted; older labs generally require re-draw.
A telehealth provider that prescribes hormones without labs or a health-history review is operating below the clinical standard — not faster than it.
What does the HRT clinical evaluation cover?
Lab values alone are not sufficient for HRT prescribing decisions. A complete clinical evaluation also covers:
Symptom review
Vasomotor symptoms (hot flashes, night sweats), sleep disruption, mood changes, vaginal dryness, urinary symptoms, cognitive changes, and libido concerns are the most commonly cited drivers for seeking HRT. A structured symptom review helps the clinician characterize which symptoms are most impactful and which forms of HRT are most appropriate.
Personal and family health history
Certain conditions require careful evaluation before prescribing HRT. A responsible clinician reviews for:
- Hormone-sensitive cancers: Active or recent breast cancer, endometrial cancer, or other hormone-sensitive malignancies are important contraindications to evaluate. Family history of breast cancer is a relevant risk-benefit factor.
- Thromboembolic history: DVT, PE, or conditions that increase clotting risk may affect the choice of HRT route (transdermal estradiol carries a lower thromboembolic risk than oral estradiol for susceptible individuals).
- Cardiovascular history:The timing of HRT initiation relative to menopause onset affects cardiovascular risk-benefit calculus (the “timing hypothesis” from the Women’s Health Initiative reanalysis). Active or recent cardiovascular disease requires careful evaluation.
- Uterine status: Women with an intact uterus who take estrogen must also take a progestogen (progesterone or a progestin) to protect the uterine lining against endometrial hyperplasia. Women who have had a hysterectomy do not require a progestogen with estrogen. This is not optional — endometrial protection is a clinical requirement, not a preference.
Form and route selection
The form of HRT prescribed is a clinical decision that reflects your symptom profile, health history, personal preferences, and contraindication evaluation. Available forms through telehealth prescribers include:
- Transdermal estradiol (patches, gels, sprays) — bypasses first-pass liver metabolism; lower thromboembolic risk than oral; often preferred for women with cardiovascular risk factors
- Oral estradiol — convenient and familiar; slightly higher thromboembolic and triglyceride-raising potential than transdermal in susceptible individuals
- Vaginal estradiol (cream, ring, tablet) — localized treatment for genitourinary symptoms; minimal systemic absorption; appropriate even for some women who cannot use systemic HRT
- Micronized progesterone (oral) — the FDA-approved bioidentical progesterone; better lipid and sleep profile than synthetic progestins for many patients
- Compounded formulations — available through licensed USA 503A pharmacies for customized doses, combinations, or delivery routes not available commercially. The NAMS 2022 position statement recommends FDA-approved HRT as the first-line standard; compounded formulations are appropriate when customization has a clear clinical rationale.
| Form | Route | Primary use | Key consideration |
|---|---|---|---|
| Transdermal estradiol | Patch, gel, spray | Systemic estrogen replacement | Lower thromboembolic risk than oral; bypasses liver first-pass |
| Oral estradiol | Tablet / capsule | Systemic estrogen replacement | Convenient; slightly higher thromboembolic potential in susceptible individuals |
| Vaginal estradiol | Cream, ring, tablet | Genitourinary symptoms | Minimal systemic absorption; appropriate even for some who cannot use systemic HRT |
| Micronized progesterone | Oral (Prometrium) | Endometrial protection in women with intact uterus | FDA-approved bioidentical progesterone; favorable sleep profile vs. synthetic progestins |
| Compounded formulations | Varies | Customized dose / combination | 503A licensed USA pharmacy; appropriate when commercial form does not meet clinical need |
What should you look for in HRT pharmacy sourcing?
Whether the HRT prescribed is a commercially available FDA-approved product or a compounded formulation, the pharmacy matters.
- FDA-approved commercial products (Climara, Vivelle-Dot, Estrace, Prometrium, and generics) are manufactured under FDA oversight. They are available through any licensed retail pharmacy.
- Compounded HRT should come only from a licensed USA 503A compounding pharmacy. These pharmacies operate under state board licensure and USP compounding standards. A legitimate telehealth provider can name the pharmacy and you can verify its licensure through your state pharmacy board.
- Overseas or unverified sources carry significant risks for hormone preparations: inaccurate concentration, unknown purity, sterility concerns, and no accountability chain. These are not legitimate HRT sources regardless of how they are marketed.
The PepScribe standard for compounded medications: licensed USA 503A pharmacies only. No hidden overseas supply chain.
What monitoring should you expect after starting HRT?
HRT is not a one-time prescription. Monitoring is required to confirm that the therapy is achieving its goals, that hormone levels are in the appropriate range, and to catch any adverse effects early.
- Symptom check-in at 8-12 weeks: Most clinicians schedule a follow-up 8-12 weeks after initiating HRT to evaluate symptom response and tolerability before any adjustments.
- Follow-up labs: A repeat hormone panel (estradiol, FSH, and any others relevant to the specific protocol) at 3-6 months helps confirm that serum levels are in the appropriate therapeutic range for your clinical picture.
- Annual review: Annual assessment of the continued need for HRT, ongoing symptom benefit, and any emerging health changes that might affect risk-benefit calculus is standard ongoing care.
A telehealth provider that issues a prescription and provides no structured follow-up pathway is not a complete clinical program. The monitoring cadence is not bureaucratic overhead — it is the mechanism that keeps hormone therapy safe and effective over time.
Frequently asked questions
Can I get HRT through telehealth?
Yes. Hormone replacement therapy — estrogen, progesterone, and in some cases testosterone for women — can be prescribed and managed through telehealth with appropriate clinical evaluation and lab monitoring. A licensed physician or nurse practitioner reviews your symptom history, lab work, and health history before any prescription is generated. This is the same clinical standard as in-person prescribing, delivered through a different channel.
What labs are required for HRT?
Lab requirements vary by the specific hormones being considered and by your provider's clinical approach. For estrogen and progesterone therapy, a typical baseline panel includes: estradiol, FSH (follicle-stimulating hormone), and LH — to characterize where you are in the menopause transition. A comprehensive metabolic panel and lipid panel are typically included as a safety baseline. If testosterone for women is being considered, free and total testosterone and SHBG are also needed. Labs taken within approximately 60 days are generally accepted; older results typically require re-draw.
What forms of HRT are available through telehealth?
Telehealth providers can prescribe the same forms of HRT as in-person clinicians: oral estradiol tablets or capsules, transdermal estradiol patches or gels, vaginal estradiol (cream, ring, tablet), micronized progesterone (oral), and progestins. Compounded formulations — including bioidentical estradiol and progesterone compounded by licensed 503A pharmacies — are also available through telehealth. The appropriate form depends on your symptoms, health history, and clinical evaluation.
How long does it take to get an HRT prescription through telehealth?
Most telehealth HRT providers complete the clinical evaluation within 48-72 hours of receiving your completed intake and lab results. Labs are often the rate-limiting step — if you are using your own recent labs, the process is faster. If labs are ordered as part of the intake, add the time for a blood draw at a local lab plus processing time (typically 1-3 days). Once prescribed, the medication ships from a licensed pharmacy and typically arrives within 3-5 business days.
Is compounded HRT the same as FDA-approved hormone therapy?
No. Compounded hormone therapy is prepared by a licensed compounding pharmacy to a specific prescription — it is not the same as FDA-approved hormone medications. FDA-approved hormone therapies (such as Climara, Vivelle-Dot, Prometrium, and others) have undergone clinical trials for safety and efficacy; compounded preparations have not. Compounded HRT can be appropriate when a customized dose, concentration, or delivery form is clinically indicated for a specific patient — this is a decision made with your clinician. The NAMS 2022 position statement recommends FDA-approved hormone therapy as the standard first-line approach.
What are the risks of getting HRT online from an unreliable provider?
The risks of inadequate clinical oversight for HRT are real: prescribing without labs or without reviewing personal and family health history misses important contraindications (active or recent hormone-sensitive cancers, untreated endometrial hyperplasia, certain cardiovascular conditions, and active thromboembolic disease are all reasons to evaluate HRT carefully rather than prescribe it routinely). Pharmacy quality matters too — compounded medications from unlicensed or overseas sources carry purity, concentration, and sterility risks. A responsible telehealth HRT provider requires labs, reviews your history, and uses licensed USA pharmacies.